Arkolith/Insider Trading/CTMX/Form 4

Ogden Christopher

Chief Financial OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4 · filed Aug 22, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 20, 2024Option exercise(M)7K—$0110K
Aug 20, 2024Sell(S)2K$1.23$2K108K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 20, 2024Option exercise(M)7K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000433) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML